According to Zacks, “Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company’s product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. “
Other research analysts have also issued reports about the stock. BidaskClub raised shares of Urovant Sciences from a strong sell rating to a sell rating in a research note on Thursday. HC Wainwright dropped their price objective on shares of Urovant Sciences from $33.00 to $28.00 and set a buy rating on the stock in a research note on Friday, June 19th.
Shares of Urovant Sciences stock traded down $0.32 during trading on Thursday, hitting $8.05. 9 shares of the stock were exchanged, compared to its average volume of 69,907. The stock has a market capitalization of $260.68 million, a price-to-earnings ratio of -1.72 and a beta of 1.29. The company has a fifty day moving average price of $8.99 and a 200-day moving average price of $10.02. Urovant Sciences has a 1-year low of $6.55 and a 1-year high of $15.98.
Urovant Sciences (NASDAQ:UROV) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.37. Equities research analysts expect that Urovant Sciences will post -6.78 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. bought a new position in shares of Urovant Sciences during the first quarter valued at about $49,000. Royal Bank of Canada increased its position in Urovant Sciences by 2,950.8% during the 1st quarter. Royal Bank of Canada now owns 9,305 shares of the company’s stock valued at $86,000 after purchasing an additional 9,000 shares during the period. Vigilare Wealth Management purchased a new position in Urovant Sciences during the 2nd quarter valued at $100,000. First Trust Advisors LP increased its position in Urovant Sciences by 8.1% during the 2nd quarter. First Trust Advisors LP now owns 15,299 shares of the company’s stock valued at $151,000 after purchasing an additional 1,144 shares during the period. Finally, Marshall Wace LLP purchased a new position in Urovant Sciences during the 1st quarter valued at $325,000. 23.81% of the stock is currently owned by institutional investors.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Read More: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.